APO RESEARCH · REPORT
Gene Therapy On Cardiovascular Disease
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Product & engineering
Understand the product.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Selected research
Industry Growth & Trends
Global Gene Therapy On Cardiovascular Disease Industry Growth and Trends Forecast to 2032
Market perspective
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
According to APO Research, the global Gene Therapy On Cardiovascular Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Gene Therapy On Cardiovascular Disease market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Gene Therapy On Cardiovascular Disease market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gene Therapy On Cardiovascular Disease market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gene Therapy On Cardiovascular Disease.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Gene Therapy On Cardiovascular Disease market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Gene Therapy On Cardiovascular Disease Market by Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Gene Therapy On Cardiovascular Disease Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease Segment by Application
Heart Disease
Vascular Disease
Gene Therapy On Cardiovascular Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Gene Therapy On Cardiovascular Disease companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-Viral Gene Therapy
Applications
- Heart Disease
- Vascular Disease
Companies covered
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Gene Therapy On Cardiovascular Disease Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2021-2032)
- 1.4.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2021-2026)
- 1.4.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2027-2032)
- 1.5 Key Regions Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 1.5.1 North America Gene Therapy On Cardiovascular Disease Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Gene Therapy On Cardiovascular Disease Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Growth Rate (2021-2032)
- 1.5.4 South America Gene Therapy On Cardiovascular Disease Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size Growth Rate (2021-2032)
2 Gene Therapy On Cardiovascular Disease Market by Type
- 2.1 Type Introduction
- 2.1.1 Viral Gene Therapy
- 2.1.2 Non-Viral Gene Therapy
- 2.2 Global Gene Therapy On Cardiovascular Disease Market Size by Type
- 2.2.1 Global Gene Therapy On Cardiovascular Disease Market Size Overview by Type (2021-2032)
- 2.2.2 Global Gene Therapy On Cardiovascular Disease Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Gene Therapy On Cardiovascular Disease Market Size Forecasted by Type (2027-2032)
- 2.3 Global Gene Therapy On Cardiovascular Disease Market Size by Regions
- 2.3.1 North America Gene Therapy On Cardiovascular Disease Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Gene Therapy On Cardiovascular Disease Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Gene Therapy On Cardiovascular Disease Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Gene Therapy On Cardiovascular Disease Market Size Breakdown by Type (2021-2026)
3 Gene Therapy On Cardiovascular Disease Market by Application
- 3.1 Type Introduction
- 3.1.1 Heart Disease
- 3.1.2 Vascular Disease
- 3.2 Global Gene Therapy On Cardiovascular Disease Market Size by Application
- 3.2.1 Global Gene Therapy On Cardiovascular Disease Market Size Overview by Application (2021-2032)
- 3.2.2 Global Gene Therapy On Cardiovascular Disease Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Gene Therapy On Cardiovascular Disease Market Size Forecasted by Application (2027-2032)
- 3.3 Global Gene Therapy On Cardiovascular Disease Market Size by Regions
- 3.3.1 North America Gene Therapy On Cardiovascular Disease Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Gene Therapy On Cardiovascular Disease Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Gene Therapy On Cardiovascular Disease Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Gene Therapy On Cardiovascular Disease Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Gene Therapy On Cardiovascular Disease Industry Trends
- 4.2 Gene Therapy On Cardiovascular Disease Industry Drivers
- 4.3 Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges
- 4.4 Gene Therapy On Cardiovascular Disease Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Gene Therapy On Cardiovascular Disease Revenue (2021-2026)
- 5.2 Global Gene Therapy On Cardiovascular Disease Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Gene Therapy On Cardiovascular Disease Key Company Headquarters & Area Served
- 5.4 Global Gene Therapy On Cardiovascular Disease Company, Product Type & Application
- 5.5 Global Gene Therapy On Cardiovascular Disease Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Gene Therapy On Cardiovascular Disease Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Gene Therapy On Cardiovascular Disease Players Market Share by Revenue in 2025
- 5.6.3 2025 Gene Therapy On Cardiovascular Disease Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Biogen
- 6.1.1 Biogen Company Information
- 6.1.2 Biogen Business Overview
- 6.1.3 Biogen Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.1.5 Biogen Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Gilead Sciences
- 6.3.1 Gilead Sciences Company Information
- 6.3.2 Gilead Sciences Business Overview
- 6.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.3.5 Gilead Sciences Recent Developments
- 6.4 Sarepta Therapeutics
- 6.4.1 Sarepta Therapeutics Company Information
- 6.4.2 Sarepta Therapeutics Business Overview
- 6.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.4.5 Sarepta Therapeutics Recent Developments
- 6.5 Alnylam Pharmaceuticals
- 6.5.1 Alnylam Pharmaceuticals Company Information
- 6.5.2 Alnylam Pharmaceuticals Business Overview
- 6.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.5.5 Alnylam Pharmaceuticals Recent Developments
- 6.6 Amgen
- 6.6.1 Amgen Company Information
- 6.6.2 Amgen Business Overview
- 6.6.3 Amgen Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.6.5 Amgen Recent Developments
- 6.7 Spark Therapeutics
- 6.7.1 Spark Therapeutics Company Information
- 6.7.2 Spark Therapeutics Business Overview
- 6.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.7.5 Spark Therapeutics Recent Developments
- 6.8 Akcea Therapeutics
- 6.8.1 Akcea Therapeutics Company Information
- 6.8.2 Akcea Therapeutics Business Overview
- 6.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.8.5 Akcea Therapeutics Recent Developments
- 6.9 bluebird bio
- 6.9.1 bluebird bio Company Information
- 6.9.2 bluebird bio Business Overview
- 6.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.9.5 bluebird bio Recent Developments
- 6.10 Sunway Biotech
- 6.10.1 Sunway Biotech Company Information
- 6.10.2 Sunway Biotech Business Overview
- 6.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.10.5 Sunway Biotech Recent Developments
- 6.11 SIBIONO
- 6.11.1 SIBIONO Company Information
- 6.11.2 SIBIONO Business Overview
- 6.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.11.5 SIBIONO Recent Developments
- 6.12 AnGes
- 6.12.1 AnGes Company Information
- 6.12.2 AnGes Business Overview
- 6.12.3 AnGes Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.12.5 AnGes Recent Developments
- 6.13 Orchard Therapeutics
- 6.13.1 Orchard Therapeutics Company Information
- 6.13.2 Orchard Therapeutics Business Overview
- 6.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.13.5 Orchard Therapeutics Recent Developments
- 6.14 Human Stem Cells Institute
- 6.14.1 Human Stem Cells Institute Company Information
- 6.14.2 Human Stem Cells Institute Business Overview
- 6.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
- 6.14.5 Human Stem Cells Institute Recent Developments
7 North America
- 7.1 North America Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 7.3 North America Gene Therapy On Cardiovascular Disease Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 8.3 Europe Gene Therapy On Cardiovascular Disease Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 10.3 South America Gene Therapy On Cardiovascular Disease Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst